• ISSN 16748301
  • CN 32-1810/R
Volume 32 Issue 5
May  2018
Article Contents

Citation:

Non-alcoholic fatty liver disease–a chronic disease of the 21st century

  • Received Date: 2016-11-19
    Accepted Date: 2016-12-15
  • Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of metabolic states ranging from simple steatosis o inflammation with associated fibrosis to cirrhosis. Though accumulation of hepatic fat is not associated with a ignificant increase in mortality rates, hepatic inflammation is, as this augments the risk of terminal liver disease, i.e., cirrhosis, hepatic decompensation (liver failure) and/or hepatocellular carcinoma. Disease progression is usually low, over a decade or more and, for the most part, remains asymptomatic. Recent estimates suggest that the global prevalence of NAFLD is high, about one in four. In most cases, NAFLD overlaps with overweight, obesity, cardiovascular disease and the metabolic syndrome with numerous contributing parameters including a dysregulation of adipose tissue, insulin resistance, type 2 diabetes, changes in the gut microbiome, neuronal and hormonal dysregulation and metabolic stress. NAFLD is diagnosed incidentally, despite its high prevalence. Non-invasive maging techniques have emerged, making it possible to determine degree of steatosis as well asfibrosis. Despite this, he benefit of routine diagnostics remains uncertain. A better understanding of the (molecular) pathogenesis of NAFLD is needed combined with long-term studies where benefits of treatment can be assessed to determine cost benefit ratios. This review summarizes the current state of knowledge and possible areas of treatment.
  • 加载中
  • 加载中

Article Metrics

Article views(120) PDF downloads(39) Cited by()

Related
Proportional views
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Non-alcoholic fatty liver disease–a chronic disease of the 21st century

  • 1. Cancer Research Program, Block-E, The Research Institute of the McGill University Health Centre and Department of Medicine, McGill University, Montreal QC H4A 3J1, Canada.

Abstract: Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of metabolic states ranging from simple steatosis o inflammation with associated fibrosis to cirrhosis. Though accumulation of hepatic fat is not associated with a ignificant increase in mortality rates, hepatic inflammation is, as this augments the risk of terminal liver disease, i.e., cirrhosis, hepatic decompensation (liver failure) and/or hepatocellular carcinoma. Disease progression is usually low, over a decade or more and, for the most part, remains asymptomatic. Recent estimates suggest that the global prevalence of NAFLD is high, about one in four. In most cases, NAFLD overlaps with overweight, obesity, cardiovascular disease and the metabolic syndrome with numerous contributing parameters including a dysregulation of adipose tissue, insulin resistance, type 2 diabetes, changes in the gut microbiome, neuronal and hormonal dysregulation and metabolic stress. NAFLD is diagnosed incidentally, despite its high prevalence. Non-invasive maging techniques have emerged, making it possible to determine degree of steatosis as well asfibrosis. Despite this, he benefit of routine diagnostics remains uncertain. A better understanding of the (molecular) pathogenesis of NAFLD is needed combined with long-term studies where benefits of treatment can be assessed to determine cost benefit ratios. This review summarizes the current state of knowledge and possible areas of treatment.

    HTML

Catalog

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return